Searched over 200M research papers for "squamous cell"
10 papers analyzed
These studies suggest that squamous cell carcinomas have common determinants and are influenced by factors like tobacco, alcohol, viral infections, genetic and epigenetic changes, and immune evasion strategies, with targeted therapies showing promise for treatment.
20 papers analyzed
Squamous cell carcinoma (SCC) is one of the most common types of human solid tumors, contributing significantly to cancer mortality. These tumors originate from epithelial cells and exhibit a high degree of heterogeneity. SCCs can arise from various epithelial tissues, including those that are simple or pseudo-stratified, through the activation of quiescent cells or changes in cell-fate determination.
Recent large-scale genomic, genetic, and epigenetic studies have identified common determinants across SCCs from different body sites. These determinants include specific genetic events that activate oncogenes such as ΔNp63, which plays a crucial role in sustaining malignant cell proliferation and survival by regulating transcriptional programs . The activation of oncogenic KRas and the loss of tumor suppressor p53 are also critical in the development of invasive SCCs, highlighting the need for multiple genetic hits for tumor progression.
SCCs can develop in various anatomical sites, including the head, neck, skin, and lungs. In the head and neck region, risk factors include tobacco use, alcohol dependence, and infection with oncogenic viruses such as human papillomavirus (HPV). The incidence of HPV-associated oropharyngeal cancer is rising in developed countries and may soon surpass that of cervical cancer. Sun exposure is a significant risk factor for cutaneous SCCs, which often evolve from actinic keratosis, a form of squamous cell carcinoma in situ.
The cellular origin of SCCs remains a topic of investigation. Studies using mouse models have shown that different epidermal lineages, including hair follicle stem cells and interfollicular epidermis, can initiate squamous tumors upon activation of oncogenic pathways. The tumor microenvironment also plays a critical role in SCC progression. For instance, SCCs can evade the immune response by down-regulating vascular E-selectin and recruiting regulatory T cells, which suppress immune activity. Treatment with Toll-like receptor (TLR)7 agonists like imiquimod can counteract these immune evasion strategies.
Diagnosis and treatment of SCCs vary depending on the tumor's location and stage. Early-stage head and neck SCCs are typically treated with surgery or radiotherapy, while locally advanced cases may require multimodal treatment, including chemoradiation. For recurrent or metastatic disease, chemotherapy with or without biological agents is indicated. In lung SCCs, emerging targeted therapies focus on genetic abnormalities such as SOX2 amplification and PI3K pathway changes, offering new avenues for treatment.
Squamous cell carcinoma is a complex and heterogeneous group of cancers with common genetic and epigenetic determinants. Understanding the cellular origins, risk factors, and tumor microenvironment is crucial for developing effective diagnostic and therapeutic strategies. Advances in molecular biology and targeted therapies hold promise for improving outcomes in patients with SCC.
Most relevant research papers on this topic